Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: The Saitama Medical School, albuminuria reduction in diabetics with valsartan (STAR) study

Hypertension Research

Volumn 30, Issue 6, 2007, Pages 529-533

  Katayama, Shigehiro ^a   Yagi, Shinji ^a   Yamamoto, Hitoshi ^a   Yamaguchi, Masako ^a   Izumida, Taro ^a   Noguchi, Yuichi ^a   Inaba, Munemichi ^a   Inukai, Kouichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; Calcium channel blocker; Combination therapy; Microalbuminuria; Target blood pressure

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; HUMAN ALBUMIN; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERTENSION; JAPANESE; MICROALBUMINURIA; MONOTHERAPY; RENAL PROTECTION;

AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 34447562581     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.529     Document Type: Article

References (28)

1. Statistic Committee of Japan Hemodialysis Society: An overview of dialysis treatment in Japan (as of Dec. 31, 2003). J Jpn Hemodialysis Soc 2006; 39: 1-22 (in Japanese).
2. Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383-388.
3. Kaiske BL, Kalil RSN, Ma JZ, et al: Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-138.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborate Study Group: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
5. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Parving H, Lehnert H, Broncher-Mortensen J, et al: The effect of irbesartan on the progression of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
8. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.
9. Zatz R, Dunn R, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-1930.
10. Imai E, Horio M: Prevalence and perspectives of CKD in Japan. Jpn J Nephrol 2006; 48: 703-710 (in Japanese).
11. Doublier S, Salvidio G, Lupia E, et al: Nephrin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003; 52: 1023-1030.
12. Duruvasula RV, Petermann AT, Hiromura K, et al: Activation of a local tissue angiotensin system in podocytes by mechanical stress. Kidney Int 2004; 65: 30-39.
13. Baba S, The J-MIND Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201.
14. Nathan S, Pepine CJ, Bakris GL: Calcium antagonists. Effects on cardio-renal risk in hypertensive patients. Hypertension 2005; 46: 637-642.
15. Katayama S, Inaba M, Morita T, et al: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
16. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
17. Ritz E, Orth SR, Strzelczyk P: Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens 1997; 15 (Suppl 2): S21-S26.
18. Bakris GL, Griffin KA, Picken MM, Bidani AK: Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens 1997; 15: 1181-1185.
19. Okada N, Hayashi T, Mori T, et al: Nifedipine enhances the cardioprotective effect of an angiotensin II-receptor blocker in an experimental animal model of heart failure. Hypertens Res 2005; 28: 431-438.
20. Jinno T, Iwai M, Li Z, et al: Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan. Hypertension 2004; 43: 263-269.
21. Mak TI, Boehme P, Wegliccki WB: Antioxidant effect of calcium channel blockers against free radical injury in endothelial cells. Circ Res 1992; 70: 1099-1103.
22. Ko YD, Sachinidis A, Graack GH, et al: Inhibition of angiotensin II and platelet-derived growth factor-induced vascular smooth muscle cell proliferation by calcium entry blockers. Clin Invest 1992; 70: 113-117.
23. Klag MJ, Whelton PK, Randal BL, et al: A prospective study of blood pressure and incidence of end-stage renal disease in 332,544 men. N Engl J Med 1996; 334: 13-18.
24. Lazarus JM, Bourgoignie JJ, Buckalew VM, et al, The Modification of Diet in Renal Disease Study Group: Achievment and safety of a low blood pressure goal in chronic renal disease. Hypertension 1997; 29: 641-650.
25. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS38. BMJ 1998; 317: 703-713.
26. Lewis JB, Berl T, Bain RP, et al: Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Am J Kidney Dis 1999; 34: 809-817.
27. Araki S, Haneda M, Sugimoto T, et al: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54: 2983-2987.
28. Yamada T, Komatsu M, Komiya I, et al: Development, progression, and regression of microalbuminuria in Jpanese patients with type 2 diabetes under tight glycemic and blood pressure control. Diabetes Care 2005; 28: 2733-2738.